The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

Volume: 8, Issue: 22, Pages: 6088 - 6100
Published: Jan 1, 2018
Abstract
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of...
Paper Details
Title
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
Published Date
Jan 1, 2018
Volume
8
Issue
22
Pages
6088 - 6100
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.